Abstract:LE 300 represents a structurally novel type of antagonist acting preferentially at the dopamine D1/D5 receptors and the serotonin 5-HT2A receptor. The compound consists of a 10-membered central azecine ring fused to indole on one and to benzene on the other side. To estimate the importance of the indole moiety in this highly active benz-indolo-azepine, the indole has to be removed and the "de-indolised" analog reinvestigated pharmacologically. Accordingly, we synthesized 3-benzazecines and in addition some homologuous 3-benzazonines. Methoxylated beta-phenylethylamines were treated with ethyl omega-bromo-butanoates and -pentanoates, respectively, to give the corresponding lactams which were cyclized (POCl3) and reduced (NaBH4), yielding the cis-annelated (X-ray) benzindolizines and -quinolizines. The 10- and 9-membered rings were obtained by cleavage of the central C-N bond, which was performed in the following two ways: Quarternisaion with methyl iodide and cleavage with sodium in liquid ammonia gave the NCH3 derivatives, reaction with benzyloxycarbonyl chloride/NaBH4 followed by catalytic debenzylation yielded a corresponding NH compound. Functional experiments on rat artery segments precontracted with ketanserin and radioligand binding experiments using human cloned dopamine receptor subtypes were conducted with all of the benzazecine and benzazonine derivatives. In contrast to the benz-indolo-compound LE 300 they did not show any significant affinity towards the D1, D2, D4, and D5 receptors and only moderate antagonistic activity at the 5-HT2A receptor. It can be concluded from our study that an indole moiety or at least another second aromatic system at the central azecine ring is part of the pharmacophore and thus essential for high biological activity.

Discovery of Novel Potent and Selective Ligands for 5-HT2A Receptor with Quinazoline Scaffold

Design, Synthesis, And Sar Studies Of Heteroarylpyrimidines And Heteroaryltriazines As Cb2r Ligands

Discovery of a Novel 5-HT2A inhibitor by pharmacophore-based virtual screening

Design, Synthesis, and Structure-Activity Relationship Studies of Novel Indolyalkylpiperazine Derivatives as Selective 5-HT1A Receptor Agonists

Synthesis And Characterization Of 5-Hydroxy-2-(2-Phenylethyl)Chromone (5-Hpec) And Its Analogues As Non-Nitrogenous 5-Ht2b Ligands

Isoquinolinone derivatives as potent CNS multi-receptor D2/5-HT1A/5-HT2A/5-HT6/5-HT7 agents: Synthesis and pharmacological evaluation

Dopamine/serotonin receptor ligands. Part IV [1]: synthesis and pharmacology of novel 3-benzazecines and 3-benzazonines as potential 5-HT2A and dopamine receptor ligands

Discovery and in vitro Evaluation of Novel Serotonin 5-HT2A Receptor Ligands Identified Through Virtual Screening

Novel Quinazoline Derivatives as Highly Effective A2A Adenosine Receptor Antagonists

Design, synthesis, and biological evaluation of aralkyl piperazine and piperidine derivatives targeting SSRI/5-HT1A/5-HT7

Design and synthesis of novel 3-substituted-indole derivatives as selective H3 receptor antagonists and potent free radical scavengers.

Discovery Of 1-(3,4-Dichlorophenyl)-N,N-Dimethyl-1,2,3,4-Tetrahydroquinolin-4amine, A Dual Serotonin And Dopamine Reuptake Inhibitor

‘Click’ D1 receptor agonists with a 5-HT1A receptor pharmacophore producing D2 receptor activity

Higher-Affinity Agonists of 5-HT1AR Discovered Through Tuning the Binding-Site Flexibility

Synthesis of dihydrofuroaporphine derivatives: Identification of a potent and selective serotonin 5-HT1A receptor agonist

( S )- N -Benzyl-1-phenyl-3,4-dihydroisoqunoline-2(1 H )-carboxamide Derivatives, Multi-Target Inhibitors of Monoamine Oxidase and Cholinesterase: Design, Synthesis, and Biological Activity.

Discovery of Novel Indolealkylpiperazine Derivatives As Potent 5-HT1A Receptor Agonists for the Potential Future Treatment of Depression

Design, Synthesis, and Evaluation of Indolebutylamines As a Novel Class of Selective Dopamine D3 Receptor Ligands.

Structure-based 3D-QSAR Studies on Thiazoles As 5-HT3 Receptor Antagonists

Insights into binding modes of 5-HT2c receptor antagonists with ligand-based and receptor-based methods

Design and Synthesis of Novel 2-Pyrazoline-1-ethanone Derivatives As Selective MAO Inhibitors.